Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A
Published inActa ophthalmologica, vol. 87, no. 8, p. 930-932
Publication date2009
Keywords
- Angiogenesis Inhibitors/*administration & dosage
- Antibodies, Monoclonal/*administration & dosage
- Antibodies, Monoclonal, Humanized
- Female
- Fovea Centralis/*blood supply
- Humans
- Injections, Intraocular
- Middle Aged
- Retinal Neovascularization/*drug therapy/*etiology
- Telangiectasis/classification/*complications
- Vitreous Body
Citation (ISO format)
MAVRAKANAS, Nikolaos et al. Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A. In: Acta ophthalmologica, 2009, vol. 87, n° 8, p. 930–932. doi: 10.1111/j.1755-3768.2009.01598.x
Main files (1)
Article
Identifiers
- PID : unige:19946
- DOI : 10.1111/j.1755-3768.2009.01598.x
- PMID : 19706015
ISSN of the journal1755-375X
